ANDAINJECTIONINJECTABLE
Approved
Jan 2023
Lifecycle
Post-LOE
Competitive Pressure
30/100
Data completeness
2/8 — Basic
KETAMINE HYDROCHLORIDE (ketamine hydrochloride) by Fresenius Kabi is injection, a racemic mixture of ketamine, is a non-selective, non-competitive antagonist of the n-methyl-d-aspartate (nmda) receptor, an ionotropic glutamate receptor. First approved in 2023.
Drug data last refreshed 18h ago
Mechanism of Action
Injection, a racemic mixture of ketamine, is a non-selective, non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, an ionotropic glutamate receptor. The major circulating metabolite of ketamine (norketamine) demonstrated activity at the same receptor with less affinity.…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Company
Fresenius Kabi
Worked on KETAMINE HYDROCHLORIDE at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.